Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock traded down $0.08 on Thursday, reaching $8.34. 1,380,463 shares of the stock were exchanged, compared to its average volume of 1,517,613. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The firm has a market cap of $1.19 billion, a PE ratio of -55.60 and a beta of 1.24. The firm’s 50 day moving average is $8.71 and its 200-day moving average is $7.19. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.67.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the transaction, the director now owns 13,356 shares of the company’s stock, valued at $112,591.08. This represents a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in shares of Aurinia Pharmaceuticals by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock worth $2,791,000 after purchasing an additional 77,510 shares during the period. Rhumbline Advisers lifted its holdings in Aurinia Pharmaceuticals by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 208,263 shares of the biotechnology company’s stock worth $1,189,000 after buying an additional 24,371 shares during the period. PFG Investments LLC grew its position in shares of Aurinia Pharmaceuticals by 37.9% in the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 7,900 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $1,155,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Aurinia Pharmaceuticals by 10.0% in the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 4,808 shares during the period. 36.83% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.